Neurosense Therapeutics Ltd
Change company Symbol lookup
Select an option...
NRSN Neurosense Therapeutics Ltd
EFBI Eagle Financial Bancorp Inc
CNSP CNS Pharmaceuticals Inc
DIDIY DiDi Global Inc
QLGN Qualigen Therapeutics Inc
JOFF JOFF Fintech Acquisition Corp
IR Ingersoll Rand Inc
TGT Target Corp
CCLP CSI Compressco LP
BIOT Biotech Acquisition Co
Go

Health Care : Biotechnology |
Based in Israel
Company profile

NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Postmarket

Last Trade
Delayed
$1.62
-0.026 (-1.58%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$1.65
Day's Change
0.016 (0.98%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
1.66
Day's Low
1.60
Volume
(Average)
Volume:
13,585

10-day average volume:
12,984
13,585

Upcoming Events

There are no upcoming events for NRSN

Past Earnings

This page reports .
DateEvent descriptionEarnings per
share actual
Earnings
estimate range
Previous year's
actual
May 31, 2022Q1 2022 Earnings Release-$0.24----
April 14, 2022 FY 2021 Earnings Release-$0.84-$0.84 to -$0.84--

Past IPOs

DateEvent descriptionAmount of offeringNumber of sharesExpected price range
December 9, 2021Neurosense Therapeutics Ltd Initial Public Offering$1,200,000200,000$6.00 to $6.00

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

, , , Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.